Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs

N/ACompletedNCT02005146

Fundación Pública Andaluza Progreso y Salud86 enrolled

Overview

Define the patients who lost HBsAg, studying the loss predictive factors and if there was suspension of treatment, study the evolution after that

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * \>18 years old * Chronic hepatitis B (HBeAg+ or HBeAg-) * HBsAg loss * Treated with nucleoside/nucleotide analogues * With or without previous interferon (IFN/PEG-IFN) * Patients with HBsAg loss after 2006 * Immunocompetent patients Exclusion Criteria: * Spontaneous HBsAg loss * HBsAg loss while treatment in monotherapy or combinated with IFN or PEG-IFN. * Patients with hepatitis delta virus (HDV) coinfection. * Patients with hepatitis C virus (HCV) coinfection. * Patients with HIV coinfection. * Patients with liver transplant. * Patients with reactivated hepatitis B virus (HBV) by immuno-suppressive treatment.

Locations (22)

Hospital Germans Trias i Pujol

Badalona, Barcelona, Spain

Hospital Universitario Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Outcomes

Primary Outcomes

Epidemiological characteristics from hepatitis B patients who lost HBsAg related to treatment with nucleoside/nucleotide analogues

Study the number of diferents virological, serological, clinical, histological, biochemical characteristics from hepatitis B patients who lost HBsAg related to treatment with nucleoside/nucleotide analogues.

Time frame: 15 months

Secondary Outcomes

Epidemiological characteristics in case of suspension of treatment.

Count the diferents characteristics virological, histological, serological, and the clinical course of this patients whom must to be suspended the treatment

Time frame: 15 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.